HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • On-demand Webinar
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists

ICER Report At a Glance: Beti-Cel for Beta Thalassemia

Beta Thalassemia is a blood disorder that results in dangerously low levels of functional hemoglobin and requires expensive lifelong medical care, including regular blood transfusions. Beti-cel is a gene therapy by Bluebird Bio that can potentially cure the disorder by genetically modifying a […]

more info 07/19/2022View Related Articles
Bookmark and Share

ICER Announces Initiative to Develop Health Equity-Targeted HTA Practices

Health technology assessment (HTA) agencies are primarily focused on efficacy and safety of a therapeutic on a general population. A new initiative by the Institute for Clinical and Economic Review (ICER) seeks to add another criteria to the mix: health equity. The non-profit recently received […]

more info 07/13/2022View Related Articles
Bookmark and Share

ICER Signals Concern About Price for Amylyx’s ALS Drug

The Institute for Clinical and Economic Review (ICER) has released a draft report detailing their concerns surrounding Amylyx Pharmaceutical’s new ALS drug Albrioza/AMX0035. The drug has just been conditionally approved in Canada and will likely receive a decision from the US Food and Drug […]

more info 06/15/2022View Related Articles
Bookmark and Share

ICER Will Assess Value and Effectiveness of Multiple Sclerosis Treatments

The Institute for Clinical and Economic Review (ICER) will perform value and effectiveness assessments on several drugs for multiple sclerosis. The drugs include several monoclonal antibody treatments from manufacturers like Biogen, Novartis, and Genentech and some biosimilars for Rituximab. The […]

more info 04/21/2022View Related Articles
Bookmark and Share

ICER White Paper – Rare Disease Drug Policy Reform, Drug Access, and Innovation

Despite the advancements in rare disease treatment, patients with many rare diseases still have extremely limited, if any, treatment options. Changes in regulatory approval for rare disease drugs like the Orphan Drug Act have helped to bring new treatments to the clinic, but some worry whether the […]

more info 04/07/2022View Related Articles
Bookmark and Share

ICER Will Develop California State Unsupported Price Reports

The California Health Care Foundation (CHCF) has awarded The Institute for Clinical and Economic Review (ICER) a new grant to develop 2 California-specific unsupported price increase reports. In addition, the grant will support the development of a policymaker guide to use comparative effectiveness […]

more info 03/03/2022View Related Articles
Bookmark and Share

ICER: Final Evidence Report and Policy Recommendations on Tirzepatide Now Available

The Institute for Clinical and Economic Review (ICER) just released their final evidence report on the diabetes 2 drug terzepatide. ICER found adequate evidence that Eli Lilly’s drug improved symptoms but did not find it had benefits over injectable semaglutide. The institute also determined that […]

more info 02/15/2022View Related Articles
Bookmark and Share

ICER Releases Draft Report on Plinabulin and Trilaciclib for Chemo-induced Neutropenia

The Institute for Clinical and Economic Review (ICER) has released its draft evidence report for the novel drugs plinabulin (BeyondSpring Pharmaceuticals) and trilaciclib (Cosela™, G1 Therapeutics). The report assessed the comparative clinical effectiveness and value of the two drugs that are […]

more info 01/26/2022View Related Articles
Bookmark and Share

ICER Releases Evidence Report for Type 2 Diabetes Drug Tirzepatide

The Institute for Clinical and Economic Review (ICER) has released their revised evidence report for Eli Lilly’s new type 2 diabetes drug tirzepatide. The drug is intended as an adjunct therapy for metformin and is more effective than injectable semaglutide, another adjunct therapy. A virtual public […]

more info 01/17/2022View Related Articles
Bookmark and Share

Final ICER Evidence Report on Tezepelumab for Severe Asthma

A final evidence report for the clinical effectiveness and value of Tezepelumab, a treatment for severe asthma, has been released by the Institute for Clinical and Economic Review (ICER). The report finds that although the evidence isn’t adequate to find advantages over other drugs for severe […]

more info 12/16/2021View Related Articles
Bookmark and Share

  • 1
  • 2
  • 3
  • …
  • 31
  • Next Page

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

  • RWE HEOR Manager
  • Associate Director/Director, RWE
  • Associate Director of HEOR Analytics
  • RWD Scientist - Oncology
  • Associate Director, Biostatistics
 
Syndicated Reports

Current and Future Analysis of Real World Data Market With New Business Strategies and Forecast by 2029 Parexel International Corporation, TriNetX LLC

Global Gene Therapy Report 2022-2031

Global Life Sciences Consulting Services Market valued at over $10 billion in 2021, is expected to grow at a CAGR of 10%

Economic & Related Consulting Service Revenues World Report & Database

 
White Papers

How Corporate Executives View Rising Health Care Cost and the Role of Government

Global Life Sciences Consulting Services Market valued at over $10 billion in 2021, is expected to grow at a CAGR of 10%

Build or Buy – Which Is the Right QMS Choice for Your Company?

Finland – A treasure trove for real-world evidence (RWE) research and innovation

HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Jobs
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • On-demand Webinar
    • Find Out More
  • Industry Events
    • Conferences
    • Webinars
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists